268 related articles for article (PubMed ID: 35475627)
1. How Do Lipoprotein(a) Concentrations Affect Clinical Outcomes for Patients With Stable Coronary Artery Disease Who Underwent Different Dual Antiplatelet Therapy After Percutaneous Coronary Intervention?
Cui K; Yin D; Zhu C; Song W; Wang H; Jia L; Zhang R; Wang H; Cai Z; Feng L; Dou K
J Am Heart Assoc; 2022 May; 11(9):e023578. PubMed ID: 35475627
[TBL] [Abstract][Full Text] [Related]
2. Prolonged dual antiplatelet therapy in invasively treated acute coronary syndrome patients with different lipoprotein(a) concentrations.
Cui K; Wu S; Yin D; Song W; Wang H; Zhu C; Feng L; Yang Y; Fu R; Dou K
Cardiol J; 2024; 31(1):32-44. PubMed ID: 37853822
[TBL] [Abstract][Full Text] [Related]
3. Benefit and Risk of Prolonged Dual Antiplatelet Therapy After Percutaneous Coronary Intervention With Drug-Eluting Stents in Patients With Elevated Lipoprotein(a) Concentrations.
Cui K; Wang HY; Yin D; Zhu C; Song W; Wang H; Jia L; Zhang D; Song C; Feng L; Dou K
Front Cardiovasc Med; 2021; 8():807925. PubMed ID: 34988134
[No Abstract] [Full Text] [Related]
4. [Benefits and risks of prolonged dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent in patients with stable coronary artery disease and diabetes].
Cui KY; Yin D; Feng L; Zhu CG; Song WH; Wang HJ; Jia L; Zhang D; Yuan S; Wu SY; He JN; Qiao Z; Dou KF
Zhonghua Xin Xue Guan Bing Za Zhi; 2022 May; 50(5):458-465. PubMed ID: 35589594
[No Abstract] [Full Text] [Related]
5. Percutaneous Coronary Interventions Using a Ridaforolimus-Eluting Stent in Patients at High Bleeding Risk.
Kornowski R; Konigstein M; Jonas M; Assali A; Vaknin-Assa H; Segev A; Danenberg H; Halabi M; Roguin A; Kerner A; Lev E; Karamasis GV; Johnson TW; Anderson R; Blaxill J; Jadhav S; Hoole S; Witberg G; Issever MO; Ben-Yehuda O; Baumbach A
J Am Heart Assoc; 2024 Jan; 13(2):e029051. PubMed ID: 38214256
[TBL] [Abstract][Full Text] [Related]
6. Prediction of Ischemic and Bleeding Events Using the Dual Antiplatelet Therapy Score in an Unrestricted Percutaneous Coronary Intervention Population.
Brener SJ; Kirtane AJ; Rinaldi MJ; Stuckey TD; Witzenbichler B; Weisz G; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Gurbel PA; Brodie BR; Mehran R; McAndrew T; Stone GW
Circ Cardiovasc Interv; 2018 Oct; 11(10):e006853. PubMed ID: 30354629
[TBL] [Abstract][Full Text] [Related]
7. Validating Utility of Dual Antiplatelet Therapy Score in a Large Pooled Cohort From 3 Japanese Percutaneous Coronary Intervention Studies.
Yoshikawa Y; Shiomi H; Watanabe H; Natsuaki M; Kondo H; Tamura T; Nakagawa Y; Morimoto T; Kimura T
Circulation; 2018 Feb; 137(6):551-562. PubMed ID: 28982692
[TBL] [Abstract][Full Text] [Related]
8. [Impact of prolonging dual antiplatelet therapy on long-term prognosis of elderly patients with coronary heart disease complicated with diabetes mellitus undergoing drug-eluting stent implantation].
Xu JJ; Zhu P; Song Y; Yuan DS; Jia SD; Zhao XY; Yao Y; Jiang L; Xu N; Li JX; Zhang Y; Song L; Gao LJ; Chen JL; Qiao SB; Yang YJ; Xu B; Gao RL; Yuan JQ
Zhonghua Xin Xue Guan Bing Za Zhi; 2022 May; 50(5):450-457. PubMed ID: 35589593
[No Abstract] [Full Text] [Related]
9. Benefit of Prolonged Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stent for Coronary Bifurcation Lesions: Results From the Coronary Bifurcation Stenting Registry II.
Jang WJ; Ahn SG; Song YB; Choi SH; Chun WJ; Oh JH; Cho SW; Kim BS; Yoon JH; Koo BK; Yu CW; Jang YS; Tahk SJ; Kim HS; Gwon HC; Lee SY; Hahn JY
Circ Cardiovasc Interv; 2018 Jul; 11(7):e005849. PubMed ID: 30006330
[TBL] [Abstract][Full Text] [Related]
10. Risk/Benefit Tradeoff of Prolonging Dual Antiplatelet Therapy More Than 12 Months in TWILIGHT-Like High-Risk Patients After Complex Percutaneous Coronary Intervention.
Wang HY; Dou KF; Yin D; Xu B; Zhang D; Gao RL
Am J Cardiol; 2020 Oct; 133():61-70. PubMed ID: 32811654
[TBL] [Abstract][Full Text] [Related]
11. 6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin: Final Results of the ITALIC Trial (Is There a Life for DES After Discontinuation of Clopidogrel).
Didier R; Morice MC; Barragan P; Noryani AAL; Noor HA; Majwal T; Hovasse T; Castellant P; Schneeberger M; Maillard L; Bressolette E; Wojcik J; Delarche N; Blanchard D; Jouve B; Ormezzano O; Paganelli F; Levy G; Sainsous J; Carrie D; Furber A; Berlan J; Darremont O; Le Breton H; Lyuycx-Bore A; Gommeaux A; Cassat C; Kermarrec A; Cazaux P; Druelles P; Dauphin R; Armengaud J; Dupouy P; Champagnac D; Ohlmann P; Ben Amer H; Kiss RG; Ungi I; Gilard M
JACC Cardiovasc Interv; 2017 Jun; 10(12):1202-1210. PubMed ID: 28641840
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes of patients treated using very short duration dual antiplatelet therapy after implantation of biodegradable-polymer drug-eluting stents: rationale and design of a prospective multicenter REIWA registry.
Ishida M; Takahashi F; Goto I; Niiyama M; Saitoh H; Sakamoto T; Maegawa Y; Osaki T; Nishiyama O; Endo H; Sakamoto R; Kojima T; Koeda Y; Kimura T; Itoh T; Morino Y;
Cardiovasc Interv Ther; 2020 Oct; 35(4):398-404. PubMed ID: 32776221
[TBL] [Abstract][Full Text] [Related]
13. Dual Antiplatelet Therapy for 6 Versus 18 Months After Biodegradable Polymer Drug-Eluting Stent Implantation.
Nakamura M; Iijima R; Ako J; Shinke T; Okada H; Ito Y; Ando K; Anzai H; Tanaka H; Ueda Y; Takiuchi S; Nishida Y; Ohira H; Kawaguchi K; Kadotani M; Niinuma H; Omiya K; Morita T; Zen K; Yasaka Y; Inoue K; Ishiwata S; Ochiai M; Hamasaki T; Yokoi H;
JACC Cardiovasc Interv; 2017 Jun; 10(12):1189-1198. PubMed ID: 28641838
[TBL] [Abstract][Full Text] [Related]
14. Very Short Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Patients Who Underwent Complex Percutaneous Coronary Intervention: Insight From the STOPDAPT-2 Trial.
Yamamoto K; Watanabe H; Morimoto T; Domei T; Ohya M; Ogita M; Takagi K; Suzuki H; Nikaido A; Ishii M; Fujii S; Natsuaki M; Yasuda S; Kaneko T; Tamura T; Tamura T; Abe M; Kawai K; Nakao K; Ando K; Tanabe K; Ikari Y; Igarashi Hanaoka K; Morino Y; Kozuma K; Kadota K; Furukawa Y; Nakagawa Y; Kimura T;
Circ Cardiovasc Interv; 2021 May; 14(5):e010384. PubMed ID: 34003662
[TBL] [Abstract][Full Text] [Related]
15. One-Month Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention With Zotarolimus-Eluting Stents in High-Bleeding-Risk Patients.
Kandzari DE; Kirtane AJ; Windecker S; Latib A; Kedhi E; Mehran R; Price MJ; Abizaid A; Simon DI; Worthley SG; Zaman A; Choi JW; Caputo R; Kanitkar M; McLaurin B; Potluri S; Smith T; Spriggs D; Tolleson T; Nazif T; Parke M; Lee LC; Lung TH; Stone GW;
Circ Cardiovasc Interv; 2020 Nov; 13(11):e009565. PubMed ID: 33167705
[TBL] [Abstract][Full Text] [Related]
16. Determinants and Clinical Outcomes of Extended Dual Antiplatelet Therapy over 3 Years after Drug-Eluting Stent Implantation: A Retrospective Analysis.
Lee OH; Kim BK; Hong SJ; Kim S; Ahn CM; Shin DH; Kim JS; Kang TS; Ko YG; Choi D; Hong MK; Jang Y
Yonsei Med J; 2020 Jul; 61(7):597-605. PubMed ID: 32608203
[TBL] [Abstract][Full Text] [Related]
17. New Insights Into Long- Versus Short-Term Dual Antiplatelet Therapy Duration in Patients After Stenting for Left Main Coronary Artery Disease: Findings From a Prospective Observational Study.
Wang HY; Dou KF; Guan C; Xie L; Huang Y; Zhang R; Yang W; Wu Y; Yang Y; Qiao S; Gao R; Xu B
Circ Cardiovasc Interv; 2022 Jun; 15(6):e011536. PubMed ID: 35582961
[TBL] [Abstract][Full Text] [Related]
18. Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?: A Pre-Specified Analysis From the ZEUS Trial.
Ariotti S; Adamo M; Costa F; Patialiakas A; Briguori C; Thury A; Colangelo S; Campo G; Tebaldi M; Ungi I; Tondi S; Roffi M; Menozzi A; de Cesare N; Garbo R; Meliga E; Testa L; Gabriel HM; Ferlini M; Vranckx P; Valgimigli M;
JACC Cardiovasc Interv; 2016 Mar; 9(5):426-36. PubMed ID: 26965932
[TBL] [Abstract][Full Text] [Related]
19. Benefit-Risk Profile of DAPT Continuation Beyond 1 Year after PCI in Patients with High Thrombotic Risk Features as Endorsed by 2018 ESC/EACTS Myocardial Revascularization Guideline.
Wang HY; Dou KF; Wang Y; Yin D; Xu B; Gao RL
Cardiovasc Drugs Ther; 2020 Oct; 34(5):663-675. PubMed ID: 32601780
[TBL] [Abstract][Full Text] [Related]
20. Stent Thrombosis in Drug-Eluting or Bare-Metal Stents in Patients Receiving Dual Antiplatelet Therapy.
Kereiakes DJ; Yeh RW; Massaro JM; Driscoll-Shempp P; Cutlip DE; Steg PG; Gershlick AH; Darius H; Meredith IT; Ormiston J; Tanguay JF; Windecker S; Garratt KN; Kandzari DE; Lee DP; Simon DI; Iancu AC; Trebacz J; Mauri L;
JACC Cardiovasc Interv; 2015 Oct; 8(12):1552-62. PubMed ID: 26493248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
